25/06/2026 Kymera Therapeutics completed enrollment in the Phase 2b trial of KT-621 in Atopic Dermatitis Tiziana announced that the last patient was dosed in its Phase 2 trial for the treatment of na-SPMS Leads Biolabs announced that its partner Oblenio Bio had closed a $62 million oversubscribed Series B financing to advance LBL-051 for autoimmune diseases into clinical development Kymera Therapeutics completed enrollment in the Phase 2b trial of KT-621 in Atopic Dermatitis

06/06/2026 Cullinan Therapeutics presented initial clinical data for CLN-978 at the EULAR-2026 congress Cullinan Therapeutics presented initial clinical data for CLN-978 at the EULAR-2026 congress (Ref) Cullinan Therapeutics announced that it would present initial clinical data from two ongoing Phase 1 studies of CLN-978 (CD19xCD3 T cell engager) at the EULAR-2026 congress. Clinical activity and biomarker findings in OUTRACE SLE Among 14 patients with ≥4 weeks follow up, a ≥4

23/03/2026 Gilead Sciences to acquire Ouro Medicines to advance first in class T cell engager program for autoimmune diseases Apogee Therapeutics announced Phase 2 results of zumilokibart in Moderate-to-Severe AD Galapagos and Gilead in advanced discussions to collaborate on advancing first in class T cell engager program for autoimmune diseases Kali Therapeutics announced a worldwide exclusive license agreement with Sanofi for KT501 for autoimmune diseases Gilead Sciences to